2011
DOI: 10.1001/archderm.147.12.1462
|View full text |Cite
|
Sign up to set email alerts
|

Chronic Acyclovir-Resistant HSV-2 Ulcer in an Immunosuppressed Patient Treated With Topical Cidofovir

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
5
0

Year Published

2014
2014
2024
2024

Publication Types

Select...
5
4

Relationship

0
9

Authors

Journals

citations
Cited by 14 publications
(5 citation statements)
references
References 5 publications
0
5
0
Order By: Relevance
“…Since these patients are at a higher risk of developing complications, such as dissemination of HSV to the central nervous system, appropriate prophylaxis and prompt treatment of HSV infections are imperative. [4][5][6] The reported incidence of resistance in allogeneic stem cell transplant recipients to acyclovir and valacyclovir is between 3.5% and 25% and has led to the use of alternative therapies such as topical cidofovir. [6][7][8] However, the risk of systemic toxicity from topical cidofovir is not widely reported in the literature.…”
Section: Discussionmentioning
confidence: 99%
“…Since these patients are at a higher risk of developing complications, such as dissemination of HSV to the central nervous system, appropriate prophylaxis and prompt treatment of HSV infections are imperative. [4][5][6] The reported incidence of resistance in allogeneic stem cell transplant recipients to acyclovir and valacyclovir is between 3.5% and 25% and has led to the use of alternative therapies such as topical cidofovir. [6][7][8] However, the risk of systemic toxicity from topical cidofovir is not widely reported in the literature.…”
Section: Discussionmentioning
confidence: 99%
“…This problem can be overcome by the topical use of cidofovir solution and gel. Successful treatment of ACVr HSV stomatitis by topical cidofovir in HCT patients was described in case reports [9,10,[16][17][18]. Sims et al [10] published data for the topical use of 3% cidofovir oral rinse solution, and Muluneh et al [9] reported the use of topical 1% cidofovir gel in HCT patients.…”
Section: Discussion/conclusionmentioning
confidence: 99%
“…Cidofovir has also been trialed topically in immunosuppressed patients for perianal acyclovir-and foscarnet-resistant HSV lesions with mixed efficacy. For one immunosuppressed patient treated with cidofovir 2% ointment twice daily for three weeks, significant wound healing occurred, but the lesion reappeared after therapy discontinuation [47]. In another immunosuppressed patient treated with cidofovir 1% gel, clinical improvement was noted after a week, and the lesion was shown to be HSV-negative through the use of a polymerase chain reaction on repeat testing [48] (Table 2).…”
Section: Herpes Simplex Virusmentioning
confidence: 99%